Voriconazole in the treatment of invasive mold infections in transplant recipients

被引:54
作者
Fortún, J [1 ]
Martín-Dávila, P [1 ]
Sánchez, MA [1 ]
Pintado, V [1 ]
Alvarez, ME [1 ]
Sánchez-Sousa, A [1 ]
Moreno, S [1 ]
机构
[1] Hosp Ramon y Cajal, Serv Enfermedades Infecciosas, E-28034 Madrid, Spain
关键词
D O I
10.1007/s10096-003-0960-0
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Mortality due to invasive mold infections in solid organ transplant recipients is very high despite therapy with amphotericin B, including lipid formulations. Voriconazole is a triazole with a good activity against molds, including Aspergillus spp. and Scedosporium spp. Experience with voriconazole is limited, but preliminary results in patients with these infections are promising. Reported here is the experience with voriconazole administered on a compassionate-use basis to five patients with invasive mold infections: four solid organ recipients and one patient with an autoimmune disorder. Four patients had invasive Aspergillus fumigatus infection (3 lung infections, 1 abdominal infection) and one had invasive ocular Scedosporium apiospermum infection. The MIC of voriconazole was less than or equal to1 mug/ml for all isolates (NCCLS performance standards for microdilution assay, proposed standard M38-P). Voriconazole was administered as primary therapy in a patient with Scedosporium infection and, in patients with Aspergillus infections, after persistence of positive culture despite a cumulative dose of 3 g of a lipid formulation of amphotericin B. Voriconazole was administered for a median time of 80 days (range, 60-90 days). No visual disturbances were observed, but one patient presented a moderate increase in liver enzymes. An increase in the levels of immunosuppressive drugs (tacrolimus or cyclosporine) was detected in all patients during coadministration with voriconazole. A clinical response was observed in all patients (complete response, n=3; partial response, n=2), and a microbiological response was observed in all but one patient. Furthermore, a good relationship between the MIC of voriconazole and outcome was observed. Voriconazole is an effective and safe therapy for treatment of invasive mold infections in solid organ recipients. To avoid toxicity with this drug, however, the dosing of immunosuppressive drugs must be reduced.
引用
收藏
页码:408 / 413
页数:6
相关论文
共 29 条
  • [1] Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus
    Ascioglu, S
    Rex, JH
    de Pauw, B
    Bennett, JE
    Bille, J
    Crokaert, F
    Denning, DW
    Donnelly, JP
    Edwards, JE
    Erjavec, Z
    Fiere, D
    Lortholary, O
    Maertens, J
    Meis, JF
    Patterson, TF
    Ritter, J
    Selleslag, D
    Shah, PM
    Stevens, DA
    Walsh, TJ
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) : 7 - 14
  • [2] BOWDEN R, 1998, INT IMM HOST SOC M D
  • [3] RISK-FACTORS FOR SYSTEMIC FUNGAL-INFECTIONS IN LIVER-TRANSPLANT RECIPIENTS
    BRIEGEL, J
    FORST, H
    SPILL, B
    HAAS, A
    GRABEIN, B
    HALLER, M
    KILGER, E
    JAUCH, KW
    MAAG, K
    RUCKDESCHEL, G
    PETER, K
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1995, 14 (05) : 375 - 382
  • [4] Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus
    Cuenca-Estrella, M
    Rodríguez-Tudela, JL
    Mellado, E
    Martínez-Suárez, JV
    Monzón, A
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (04) : 531 - 533
  • [5] Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
    Denning, DW
    Ribaud, P
    Milpied, N
    Caillot, D
    Herbrecht, R
    Thiel, E
    Haas, A
    Ruhnke, M
    Lode, H
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) : 563 - 571
  • [6] Therapeutic outcome in invasive aspergillosis
    Denning, DW
    [J]. CLINICAL INFECTIOUS DISEASES, 1996, 23 (03) : 608 - 615
  • [7] Invasive aspergillosis
    Denning, DW
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) : 781 - 803
  • [8] Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.:: NCCLS collaborative evaluation
    Espinel-Ingroff, A
    Bartlett, M
    Chaturvedi, V
    Ghannoum, M
    Hazen, KC
    Pfaller, MA
    Rinaldi, M
    Walsh, TJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) : 1828 - 1835
  • [9] In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi
    Espinel-Ingroff, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (03) : 954 - 958
  • [10] GALLIS HA, 1990, REV INFECT DIS, V12, P308